Keros Therapeutics, Inc. (KROS) Free cash flow 2019–2025
Keros Therapeutics, Inc. (KROS) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
$106.0MFY2025 · since FY2019: -$16.3M → $106.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $106.0M | +165.1% |
| FY2024 | -$162.8M | -28.2% |
| FY2023 | -$127.0M | -78.1% |
| FY2022 | -$71.3M | -12.9% |
| FY2021 | -$63.2M | -69.9% |
| FY2020 | -$37.2M | -128.6% |
| FY2019 | -$16.3M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice